BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danese S. Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol. 2008;29:555-564. [PMID: 18838297 DOI: 10.1016/j.it.2008.07.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res. 2010;59:791-808. [PMID: 20593217 DOI: 10.1007/s00011-010-0208-2] [Cited by in Crossref: 141] [Cited by in F6Publishing: 139] [Article Influence: 11.8] [Reference Citation Analysis]
2 Scarpa M, Kessler S, Sadler T, West G, Homer C, McDonald C, de la Motte C, Fiocchi C, Stylianou E. The epithelial danger signal IL-1α is a potent activator of fibroblasts and reactivator of intestinal inflammation. Am J Pathol 2015;185:1624-37. [PMID: 25864926 DOI: 10.1016/j.ajpath.2015.02.018] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
3 Kurishima A, Inaba M, Sakaguchi Y, Fukui T, Uchida K, Nishio A, Nomura S, Okazaki K. Immunoregulatory function of PIR-A/B+ DCs in the inflammatory responses of dextran sodium sulfate-induced colitis. J Gastroenterol 2014;49:1367-77. [DOI: 10.1007/s00535-013-0879-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Allocca M, Fiorino G, Vermeire S, Reinisch W, Cataldi F, Danese S. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. Expert Review of Clinical Immunology 2014;10:885-95. [DOI: 10.1586/1744666x.2014.917962] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Higgins PD, Johnson LA, Sauder K, Moons D, Blanco L, Taube S, Wobus CE. Transient or persistent norovirus infection does not alter the pathology of Salmonella typhimurium induced intestinal inflammation and fibrosis in mice. Comp Immunol Microbiol Infect Dis 2011;34:247-57. [PMID: 21237511 DOI: 10.1016/j.cimid.2010.12.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
6 Borensztajn K, Peppelenbosch MP, Spek CA. Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease? Trends in Pharmacological Sciences 2009;30:8-16. [DOI: 10.1016/j.tips.2008.10.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
7 Niu XJ, Xu JY, Song JH. Biological therapies for inflammatory bowel diseases. Shijie Huaren Xiaohua Zazhi 2013; 21(32): 3514-3519 [DOI: 10.11569/wcjd.v21.i32.3514] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Moon W. Golimumab Therapy in Ulcerative Colitis. Korean J Gastroenterol 2016;67:64. [DOI: 10.4166/kjg.2016.67.2.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Krzystek-Korpacka M, Neubauer K, Matusiewicz M. Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease. Clin Biochem. 2009;42:1602-1609. [PMID: 19679116 DOI: 10.1016/j.clinbiochem.2009.08.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
10 Pucchio TD, Danese S, Cristofaro RD, Rutella S. Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opinion on Therapeutic Patents 2010;20:229-50. [DOI: 10.1517/13543770903512974] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
11 Danese S, Fiocchi C, Panés J. Drug development in IBD: from novel target identification to early clinical trials. Gut 2016;65:1233-9. [PMID: 27196598 DOI: 10.1136/gutjnl-2016-311717] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
12 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, Papa G, Gasbarrini A. Biological therapies for inflammatory bowel disease: controversies and future options. Expert Rev Clin Pharmacol. 2009;2:391-403. [PMID: 22112183 DOI: 10.1586/ecp.09.12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
13 Vitale S, Strisciuglio C, Pisapia L, Miele E, Barba P, Vitale A, Cenni S, Bassi V, Maglio M, Del Pozzo G, Troncone R, Staiano A, Gianfrani C. Cytokine production profile in intestinal mucosa of paediatric inflammatory bowel disease.PLoS One. 2017;12:e0182313. [PMID: 28797042 DOI: 10.1371/journal.pone.0182313] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
14 Chakilam S, Gandesiri M, Rau TT, Agaimy A, Vijayalakshmi M, Ivanovska J, Wirtz RM, Schulze-Luehrmann J, Benderska N, Wittkopf N, Chellappan A, Ruemmele P, Vieth M, Rave-Fränk M, Christiansen H, Hartmann A, Neufert C, Atreya R, Becker C, Steinberg P, Schneider-Stock R. Death-associated protein kinase controls STAT3 activity in intestinal epithelial cells. Am J Pathol 2013;182:1005-20. [PMID: 23438478 DOI: 10.1016/j.ajpath.2012.11.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
15 Vetrano S, Ploplis VA, Sala E, Sandoval-Cooper M, Donahue DL, Correale C, Arena V, Spinelli A, Repici A, Malesci A. Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation. Proc Natl Acad Sci U S A. 2011;108:19830-19835. [PMID: 22109555 DOI: 10.1073/pnas.1107140108] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
16 Rutella S, Vetrano S, Correale C, Graziani C, Sturm A, Spinelli A, De Cristofaro R, Repici A, Malesci A, Danese S. Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature. J Cell Mol Med. 2011;15:625-634. [PMID: 20158572 DOI: 10.1111/j.1582-4934.2010.01033.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
17 Degagné E, Turgeon N, Moore-Gagné J, Asselin C, Gendron FP. P2Y(2) receptor expression is regulated by C/EBPβ during inflammation in intestinal epithelial cells. FEBS J 2012;279:2957-65. [PMID: 22742194 DOI: 10.1111/j.1742-4658.2012.08676.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
18 Striz I, Brabcova E, Kolesar L, Sekerkova A. Cytokine networking of innate immunity cells: a potential target of therapy. Clinical Science 2014;126:593-612. [DOI: 10.1042/cs20130497] [Cited by in Crossref: 133] [Cited by in F6Publishing: 54] [Article Influence: 16.6] [Reference Citation Analysis]
19 Kemp R, Dunn E, Schultz M. Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents. BioDrugs 2013;27:585-90. [PMID: 23749336 DOI: 10.1007/s40259-013-0045-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
20 Schirbel A, Kessler S, Rieder F, West G, Rebert N, Asosingh K, McDonald C, Fiocchi C. Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology 2013;144:613-623.e9. [PMID: 23149220 DOI: 10.1053/j.gastro.2012.11.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
21 Vitale S, Picascia S, Gianfrani C. The cross-talk between enterocytes and intraepithelial lymphocytes. Mol Cell Pediatr 2016;3:20. [PMID: 27251606 DOI: 10.1186/s40348-016-0048-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
22 Jackson H, Menikou S, Hamilton S, McArdle A, Shimizu C, Galassini R, Huang H, Kim J, Tremoulet A, Thorne A, Fischer R, de Jonge MI, Kuijpers T, Wright V, Burns JC, Casals-Pascual C, Herberg J, Levin M, Kaforou M, On Behalf Of The Perform Consortium. Kawasaki Disease Patient Stratification and Pathway Analysis Based on Host Transcriptomic and Proteomic Profiles. Int J Mol Sci 2021;22:5655. [PMID: 34073389 DOI: 10.3390/ijms22115655] [Reference Citation Analysis]
23 Speca S, Giusti I, Rieder F, Latella G. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 2012; 18(28): 3635-3661 [PMID: 22851857 DOI: 10.3748/wjg.v18.i28.3635] [Cited by in CrossRef: 140] [Cited by in F6Publishing: 125] [Article Influence: 14.0] [Reference Citation Analysis]
24 Al-Araimi A, Al Kharusi A, Bani Oraba A, Al-Maney MM, Al Sinawi S, Al-Haddabi I, Zadjali F. Deletion of SOCS2 Reduces Post-Colitis Fibrosis via Alteration of the TGFβ Pathway. Int J Mol Sci 2020;21:E3073. [PMID: 32349250 DOI: 10.3390/ijms21093073] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Rumessen JJ, Vanderwinden JM, Horn T. Crohn's disease of the colon: ultrastructural changes in submuscular interstitial cells of Cajal. Cell Tissue Res 2011;343:421-8. [PMID: 21120534 DOI: 10.1007/s00441-010-1087-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
26 D’Alessio S, Correale C, Tacconi C, Gandelli A, Pietrogrande G, Vetrano S, Genua M, Arena V, Spinelli A, Peyrin-Biroulet L. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest. 2014;124:3863-3878. [PMID: 25105363 DOI: 10.1172/jci72189] [Cited by in Crossref: 136] [Cited by in F6Publishing: 84] [Article Influence: 17.0] [Reference Citation Analysis]
27 Caviglia GP, Rosso C, Ribaldone DG, Dughera F, Fagoonee S, Astegiano M, Pellicano R. Physiopathology of intestinal barrier and the role of zonulin. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.19.02554-0] [Cited by in Crossref: 41] [Article Influence: 13.7] [Reference Citation Analysis]
28 Danese S. Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2011;300:G716-22. [PMID: 21233277 DOI: 10.1152/ajpgi.00472.2010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
29 Steinbach EC, Plevy SE. The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis. 2014;20:166-175. [PMID: 23974993 DOI: 10.1097/mib.0b013e3182a69dca] [Cited by in Crossref: 123] [Cited by in F6Publishing: 77] [Article Influence: 15.4] [Reference Citation Analysis]
30 Petrovic SS, Vasiljevska MM, Obradovic SD, Tarabar DK, Doder RB, Majstorovic IJ, Petrovic MD, Magic ZM, Cikota BM, Perisic NJ, Brcerevic IA, Manojlovic NS, Rancic NK. Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice. Turk J Gastroenterol 2020;31:451-8. [PMID: 32721916 DOI: 10.5152/tjg.2020.19454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Rutella S, Locatelli F. Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2011; 17(33): 3761-3775 [PMID: 21987618 DOI: 10.3748/wjg.v17.i33.3761] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
32 Scaldaferri F, Correale C, Gasbarrini A, Danese S. Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment. Cell Adh Migr 2009;3:296-9. [PMID: 19571660 DOI: 10.4161/cam.3.3.9152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
33 Matsui F, Inaba M, Uchida K, Nishio A, Fukui T, Yoshimura H, Satake A, Yoshioka K, Nomura S, Okazaki K. Induction of PIR-A/B+ DCs in the in vitro inflammatory condition and their immunoregulatory function. J Gastroenterol 2018;53:1131-41. [PMID: 29508072 DOI: 10.1007/s00535-018-1447-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Kang H, Park Y, Lee A, Seo H, Kim MJ, Choi J, Jo HN, Jeong HN, Cho JG, Chang W, Lee MS, Jeon R, Kim J. Negative regulation of NOD1 mediated angiogenesis by PPARγ-regulated miR-125a. Biochem Biophys Res Commun 2017;482:28-34. [PMID: 27836539 DOI: 10.1016/j.bbrc.2016.11.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
35 Manolakis AC, Christodoulidis G, Kapsoritakis AN, Georgoulias P, Tiaka EK, Oikonomou K, Valotassiou VJ, Potamianos SP. α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease. World J Gastroenterol 2017; 23(3): 437-446 [PMID: 28210079 DOI: 10.3748/wjg.v23.i3.437] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
36 Voudoukis E, Karmiris K, Koutroubakis IE. Multipotent role of platelets in inflammatory bowel diseases: A clinical approach. World J Gastroenterol 2014; 20(12): 3180-3190 [PMID: 24696603 DOI: 10.3748/wjg.v20.i12.3180] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]